Disease-associated XMRV sequences are consistent with laboratory contamination
-
* Corresponding authors: Paul Kellam pk5@sanger.ac.uk - Greg J Towers g.towers@ucl.ac.uk
- † Equal contributors
Retrovirology 2010, 7:111 doi:10.1186/1742-4690-7-111
Evaulated on
Faculty of 1000
Accesses
- Last 30 days: 341 accesses
- Last 365 days: 4193 accesses
- All time: 15858 accesses
Cited by
BioMed Central: 4 citations
|
Review
Fabiola Martin, Charles RM Bangham, Vincenzo Ciminale, Michael D Lairmore, Edward L Murphy, William M Switzer, Renaud Mahieux Retrovirology 2011, 8:86 (28 October 2011) This report summarizes presentations made at the June 2011, 15th International Conference on Human Retrovirology: HTLV and Related Viruses.
|
|
Editorial
Equal versus equivalent access to the scientific literature Kuan-Teh Jeang Retrovirology 2011, 8:83 (21 October 2011) The concepts of equal versus equivalent access to the scientific literature are discussed.
|
|
Research
Mir A Ali, Janet K Dale, Christine A Kozak, Raphaela Goldbach-Mansky, Frederick W Miller, Stephen E Straus, Jeffrey I Cohen Virology Journal 2011, 8:450 (24 September 2011) |
|
Viewpoints
Robert A Smith Retrovirology 2010, 7:112 (20 December 2010) Efforts to assess the prevalence of xenotropic murine leukemia virus-related virus (XMRV) in patients with prostate cancer and chronic fatigue syndrome have relied heavily on PCR-based testing of clinical samples and have yielded widely divergent findings. This week in Retrovirology, reports from four independent research groups illustrate the extreme care needed to exclude DNA or RNA contamination in PCR analyses of XMRV. In addition, phylogenetic evidence suggesting that previously-published XMRV sequences originated from a commonly-used prostate carcinoma cell line (22Rv1) is presented. These findings raise important questions regarding the provenance of XMRV and its potential connection to human disease.
|